Irish differences from the UK position — what changed since — setting out what I have, and where I think it stops being reliable.
What changes if the standard account of Irish differences is wrong? I ask because I have been treating it as settled and I noticed this week that I could not say why.
Working through the consequences rather than the evidence, since others here are better placed on the evidence.
Clear enough that I do not think I have a follow-up, which is unusual.
Narrowing post #2, because the general version has more than one answer.
For anyone finding this later: the short answer on Irish differences is that it depends on one thing, and the rest of the thread is people identifying which thing.
Worth separating Irish differences as a question about the compound from Irish differences as a question about the documentation. They get answered by different people and only one of them is answerable here.
Pharmacy practice varies between pharmacies and is not deducible from the regulatory position. Two people can honestly report opposite experiences.
The arithmetic in post #7 is right; the assumption feeding it is the part to check.
Anyone quoting an eligibility threshold should say which document it comes from. The thresholds have changed and the old ones are still circulating.
On post #7 — agreed on the reasoning, with one qualification.
Private prescribing arrangements differ in what they include, and the differences are more consequential than the headline price.
Not the whole picture, but the part of it I can speak to.
Picking up post #7: that is the part I would want checked first.
I would put moderate confidence on the mainstream reading of Irish differences and no more. That is not scepticism for its own sake; it is where the sourcing actually stops.
Adding the measurement that post #8 says would settle it.
My understanding of Irish differences is a few years old and may have been superseded. If it has been, I would genuinely like to know rather than keep repeating it.
Supply and shortage resilience: both UK and Ireland sourced primarily from European suppliers until recent disruptions. Domestic availability and pricing changed.
It is worth stating the boring hypothesis before the interesting one.
Adding what did not work for me on Irish differences, since the failures never get written up and they are half the useful information.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Irish differences from the UK position
Posting this under the heading it deserves: Irish differences from the UK position Everything below is what sits behind that. Trying to establish the boundary conditions on irish differences. The general…
|
+62 | 66 | 993 | 21mo |
|
NHS criteria and how they are applied in practice — the long version
Posting this under the heading it deserves: NHS criteria and how they are applied in practice — the long version Everything below is what sits behind that. A narrow question about NHS criteria, deliberately…
|
+11 | 15 | 11k | 9mo |
|
Coming back to: Private prescribing in the UK: what is actually involved
Private prescribing in the UK: what is actually involved Writing it up because I had to work it out twice and would rather nobody else did. I would like to know what people here actually do about Private…
|
+62 | 67 | 2.1k | 6mo |
|
UK access routes, dated and sourced
UK access routes, dated and sourced Writing it up because I had to work it out twice and would rather nobody else did. Regional question, dated June 2026, because everything in this category expires. The…
|
2 | 5.8k | 15mo | |
|
Private prescribing in the UK: what is actually involved
On the subject in the title: Private prescribing in the UK: what is actually involved Working notes rather than a conclusion. The question about private prescribing that I actually want answered is the second…
|
+66 | 76 | 46k | 14h |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Second pass at: Reimbursement variation across member states
On the subject in the title: Second pass at: Reimbursement variation across member states Working notes rather than a conclusion. The question about Reimbursement variation across member states that I…
|
+23 | 28 | 45k | 21mo |
|
Second pass at: Manufacturer assistance programmes and their eligibility rules
Second pass at: Manufacturer assistance programmes and their eligibility rules — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…
|
+13 | 17 | 1.8k | 16mo |
|
Research-use-only labelling: what it means and what it does not
Posting this under the heading it deserves: Research-use-only labelling: what it means and what it does not Everything below is what sits behind that. A labelling question, and I would like the answer to be…
|
+100 | 110 | 37k | 5mo |
|
Revisiting: Why a compound being unapproved is not the same as being illegal to possess
On the subject in the title: Revisiting: Why a compound being unapproved is not the same as being illegal to possess Working notes rather than a conclusion. I would like to know what people here actually do…
|
+76 | 82 | 52k | 11mo |
|
About the Pricing category
List prices, negotiated prices, and cost per milligram compared honestly across formats. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
|
+1 | 5 | 18k | 15mo |